Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
No one on the platform currently holds ACCD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 305,836 | $1.0M |
No one on the platform has traded ACCD yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ACCD $7.02 bid. *DAC (7) $4.62. EXIT $12.00. BRIEF: Accolade: Transcarent announced the successful completion of its merger with Accolade. note: The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
View on StockTwits ↗
$ACCD $7.02 bid. * DAC (dollar average cost includes 7 transactions to reduce cost to $4.62). Last at $3.60 (6.28.24). CHANGE EXIT TO $12.00 FROM $8.50. UPDATE: The merger is tentatively scheduled to close prior to the market open on April 8, 2025, subject to regulatory approval. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 8th) and will be suspended effective April 9, 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
View on StockTwits ↗
$ACCD Digging ACCD's personalized healthcare play. Innovative data-driven approach targeting complex healthcare navigation. Watching how they scale and expand their member base. Potential long-term healthcare tech winner. great article: https://beyondspx.com/article/accolade-accd-delivering-personalized-healthcare-solutions-at-scale
View on StockTwits ↗
$ACCD Maybe wait to see if it fills the gap around $3.70…..
View on StockTwits ↗
1. Accolade Inc. ($ACCD): A healthcare company, Accolade has experienced a significant 97% increase in its stock price over the past 30 days, indicating strong growth potential. 2. Akero Therapeutics Inc. ($AKRO): A biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH), Akero has seen its stock price rise by 96.2% over the past month. 3. OppFi Inc. ($OPFI): A financial technology company, OppFi has demonstrated a 93.1% increase in its stock price over the past 30 days, suggesting robust growth prospects.
View on StockTwits ↗
$MPLN $APPS $CRNC $TUYA what I am currently buying/accumulating; they have strong momentum & technical indicators are favorable for either near term bullish move or long term positive move. $ACCD on watch.
View on StockTwits ↗
$ACCD $5 puts exp March 21st are virtually free. Good hedge just in case things don't work out. Call it insurance.
View on StockTwits ↗
$ACCD - Accolade Inc. Common Stock - 10Q - Updated Risk Factors New risks from the pending Transcarent merger include business disruptions, employee uncertainty, legal challenges, deal restrictions, and significant fallout if it fails. Completion remains uncertain. #Risk https://d-risk.ai/ACCD/10-Q/2025-01-10
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.